Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $1.8 million.

  • Lifecore Biomedical's Share-based Compensation rose 13.58% to $1.8 million in Q2 2025 from the same period last year, while for May 2025 it was $10.2 million, marking a year-over-year increase of 63.81%. This contributed to the annual value of $10.2 million for FY2025, which is 63.81% up from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical's Share-based Compensation is $1.8 million, which was down 28.88% from $2.6 million recorded in Q1 2025.
  • Lifecore Biomedical's Share-based Compensation's 5-year high stood at $3.4 million during Q4 2024, with a 5-year trough of $620,000 in Q3 2021.
  • In the last 3 years, Lifecore Biomedical's Share-based Compensation had a median value of $1.6 million in 2023 and averaged $1.8 million.
  • In the last 5 years, Lifecore Biomedical's Share-based Compensation crashed by 30.49% in 2021 and then soared by 113.82% in 2024.
  • Lifecore Biomedical's Share-based Compensation (Quarterly) stood at $686,000 in 2021, then skyrocketed by 61.52% to $1.1 million in 2022, then spiked by 42.33% to $1.6 million in 2023, then skyrocketed by 113.82% to $3.4 million in 2024, then increased by 13.58% to $1.8 million in 2025.
  • Its Share-based Compensation was $1.8 million in Q2 2025, compared to $2.6 million in Q1 2025 and $3.4 million in Q4 2024.